

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
Stylesheet Version v1.2

EPAS ID: PAT5155945

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT
CONVEYING PARTY DATA	
Name	Execution Date
JAN JOHANSSON	03/03/2016
WALEED DANHO	03/01/2016
RECEIVING PARTY DATA	
Name:	ARTERY THERAPEUTICS, INC.
Street Address:	10 DUBERSTEIN DRIVE
City:	SAN RAMON
State/Country:	CALIFORNIA
Postal Code:	94583
PROPERTY NUMBERS Total: 1	
Property Type	Number
Application Number:	16020395
CORRESPONDENCE DATA	
Fax Number:	(415)576-0300
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
Phone:	415-576-0200
Email:	dwoodley@kilpatricktownsend.com
Correspondent Name:	KILPATRICK TOWNSEND & STOCKTON LLP
Address Line 1:	TWO EMBARCADERO CENTER, #1900
Address Line 4:	SAN FRANCISCO, CALIFORNIA 94111-3834
ATTORNEY DOCKET NUMBER:	077429-011430US-1093795
NAME OF SUBMITTER:	DORINDA WOODLEY
SIGNATURE:	/Dorinda Woodley/
DATE SIGNED:	09/24/2018
Total Attachments: 2	
source=077429_1093795_Assignment_to_Artery_09_24_2018#page1.tif	
source=077429_1093795_Assignment_to_Artery_09_24_2018#page2.tif	

Attorney Docket No. 077429-0950856 (011420US)

ASSIGNMENT
(Patent Applications)

We [1], the undersigned, have invented certain inventions and improvements disclosed in a utility (provisional or non-provisional) patent applications entitled

**"PEPTIDES HAVING REDUCED TOXICITY
THAT STIMULATE CHOLESTEROL EFFLUX",**

filed with the U.S. Patent & Trademark Office on September 10, 2015, as a US Patent Application, and given serial no. 14/774,682.

For one dollar (\$1.00) and other good and valuable consideration, the receipt and sufficiency of which we [1] acknowledge, we [1]:


1. Agree to assign, transfer, convey, and sell, hereby assign, transfer, convey, and sell and have assigned, transferred, conveyed, and sold to **Artery Therapeutics, Inc.**, a corporation of the State of California having a principal place of business at 10 Duberstein Drive, San Ramon, California 94583 ("Assignee"), the entire right, title, and interest in and to:
 - (a) all intellectual property (including, without limitation, any innovation, information, invention, discovery, product, process, work or design) disclosed, embodied, shown, or claimed in the above-referenced patent application, implicitly or explicitly;
 - (b) the above-referenced patent application, the right to claim priority to the above-referenced patent application, all applications based in whole or in part upon the above-referenced patent application, including, without limitation, all applications that are a provisional, non-provisional, design, divisional, continuation, continuation-in-part, registration, utility model, industrial design, reissue, renewal, substitute, extension, reexamination, post-grant review, inter partes review, supplemental examination or non-U.S. patent application or application for other rights based in whole or in part on the above-referenced patent application;
 - (c) all patents (including, without limitation, all U.S. and non-U.S. patents, registrations, utility models, industrial designs, design patents, counterparts, continuations, continuations-in-part, divisionals, reissues, renewals, substitutes, extensions, reexaminations, post-grant reviews, inter partes reviews and supplemental examinations) that are granted or issued upon, or that claim priority to, any and all applications described in (b) of this paragraph or that disclose or claim intellectual property described in (a) of this paragraph, in whole or in part; and
 - (d) all claims for damages by reason of past infringement of any rights under the applications or patents described in (a), (b) or (c) of this paragraph (including provisional rights to reasonable royalties pursuant to 35 U.S.C. §154(d)) and

ASSIGNMENT
USSN 14/774,682
Page 2 of 2


the right to sue for and collect such damages and royalties for Assignee's own use.

2. Authorize and request the U.S. Patent and Trademark Office or any other U.S. or non-U.S. agency to issue to the Assignee any and all patent(s), or other rights or documents, resulting from the intellectual property, patent application(s) and patents described in paragraph 1 of this Assignment.
3. Agree to sign all papers and documents, including without limitation, applications, declarations, oaths and petitions, and, at the Assignee's expense, perform any other acts that are necessary in connection with prosecution of patent application(s) or intellectual property described in paragraph 1 of this Assignment and the enforcement of patent(s) or other rights resulting from such patent application(s) or intellectual property.
4. Agree that the terms, covenants, and conditions of this Assignment shall inure to the benefit of the Assignee, its successors, assigns and other legal representative, and shall be binding upon us [me], as well as our [my] heirs, legal representatives, and assigns.
5. Promise and affirm that we have not entered, and will not enter, into any assignment, contract, or understanding that conflicts with this Assignment.
6. Authorize Kilpatrick Townsend & Stockton to insert above the application number and filing date of the above-described patent application when known.

Signed on the dates indicated beside our [my] signatures [signature].

Signature: 
Jan Johansson


Date: March 3, 2016

Signature: 
Waleed Danho

Date: March 1, 2016

ACKNOWLEDGEMENT OF ASSIGNEE:

Date: March 3, 2016

By: 
By: Jan Johansson, CEO & President
Artery Therapeutics, Inc.

LBNL Ref.: JIB 3305US-2
68136687V.1